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Abstract:
Objectives 
Intra-plaque angiogenesis and inflammation are key promoters of 
atherosclerosis and are mediated by the αvβ3 integrin pathway. We 
investigated the applicability of the αvβ3-integrin receptor-selective 
positron emission tomography (PET) radiotracer 18F-fluciclatide in 
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assessing human aortic atherosclerosis. 
Methods 
Vascular 18F-fluciclatide binding was evaluated using ex vivo analysis of 
carotid endarterectomy samples with autoradiography and 
immunohistochemistry, and in vivo kinetic modeling following radiotracer 
administration. Forty-six subjects with a spectrum of atherosclerotic 
disease categorized as stable (n=27) or unstable (n=19; recent 
myocardial infarction) underwent PET and computed tomography (CT) 
imaging of the thorax after administration of 226±13 MBq 18F-
fluciclatide. Thoracic aortic 18F-fluciclatide uptake was quantified on 
fused PET-CT images and corrected for blood-pool activity using the 
maximum tissue-to-background ratio (TBRmax). Aortic atherosclerotic 
burden was quantified by CT wall thickness, plaque volume and calcium 
scoring. 
  
Results 
18F-Fluciclatide uptake co-localised with regions of increased αvβ3 
integrin expression, and markers of inflammation and angiogenesis. 18F-
Fluciclatide vascular uptake was confirmed in vivo using kinetic 
modeling, and on static imaging correlated with measures of aortic 
atherosclerotic burden: wall thickness (r=0.57, p=0.001), total plaque 
volume (r=0.56, p=0.001) and aortic CT calcium score (r=0.37, 
p=0.01). Patients with recent myocardial infarction had greater aortic 
18F-fluciclatide uptake than those with stable disease (TBRmax 1.33 vs 
1.21, p=0.01). 
Conclusions 
In vivo expression of αvβ3 integrin in human aortic atheroma is 
associated with plaque burden and is increased in patients with recent 
myocardial infarction. Quantification of αvβ3 integrin expression with 
18F-fluciclatide PET has potential to assess plaque vulnerability and 
disease activity in atherosclerosis.
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Abstract
Objectives
Intra-plaque angiogenesis and inflammation are key promoters of 
atherosclerosis and are mediated by the αvβ3 integrin pathway. We investigated 
the applicability of the αvβ3-integrin receptor-selective positron emission 
tomography (PET) radiotracer 18F-fluciclatide in assessing human aortic 
atherosclerosis. 
Methods 
Vascular 18F-fluciclatide binding was evaluated using ex vivo analysis of 
carotid endarterectomy samples with autoradiography and 
immunohistochemistry, and in vivo kinetic modeling following radiotracer 
administration. Forty-six subjects with a spectrum of atherosclerotic disease 
categorized as stable (n=27) or unstable (n=19; recent myocardial infarction) 
underwent PET and computed tomography (CT) imaging of the thorax after 
administration of 226±13 MBq 18F-fluciclatide. Thoracic aortic 18F-fluciclatide 
uptake was quantified on fused PET-CT images and corrected for blood-pool 
activity using the maximum tissue-to-background ratio (TBRmax). Aortic 
atherosclerotic burden was quantified by CT wall thickness, plaque volume and 
calcium scoring. 
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Results
18F-Fluciclatide uptake co-localised with regions of increased αvβ3 integrin 
expression, and markers of inflammation and angiogenesis. 18F-Fluciclatide 
vascular uptake was confirmed in vivo using kinetic modeling, and on static 
imaging correlated with measures of aortic atherosclerotic burden: wall 
thickness (r=0.57, p=0.001), total plaque volume (r=0.56, p=0.001) and aortic 
CT calcium score (r=0.37, p=0.01). Patients with recent myocardial infarction 
had greater aortic 18F-fluciclatide uptake than those with stable disease 
(TBRmax 1.33 vs 1.21, p=0.01). 
Conclusions
In vivo expression of αvβ3 integrin in human aortic atheroma is associated with 
plaque burden and is increased in patients with recent myocardial infarction. 
Quantification of αvβ3 integrin expression with 18F-fluciclatide PET has 
potential to assess plaque vulnerability and disease activity in atherosclerosis.
Keywords
Atherosclerosis; positron emission tomography; integrin; computed 
tomography
Page 4 of 44
https://mc.manuscriptcentral.com/heart
Heart
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
4
Key Questions
What is already known about this subject?
The αvβ3 integrin receptor is a mediator of plaque angiogenesis and 
inflammation and has been targeted as a potential marker of atherosclerotic 
activity using PET radiotracers. As yet however, studies of αvβ3 integrin-specific 
radiotracers in humans are lacking.
What does this study add?
This is the largest study to date assessing αvβ3 integrin expression in human 
atherosclerosis. We have demonstrated that 18F-fluciclatide uptake localises 
to vascular inflammation and angiogenesis, correlates with plaque burden and 
is increased in patients with clinically unstable disease.
How might this impact on clinical practice?
Non-invasive markers of atherosclerotic disease activity may identify vulnerable 
patients and provide incremental risk prediction to current anatomic imaging 
approaches. In this study, 18F-fluciclatide shows promise as a non-invasive 
marker of disease activity and instability in atherosclerosis.
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5
Introduction
Atherosclerotic cardiovascular disease is the commonest cause of death 
worldwide, and elucidating the mechanisms underlying the propagation and 
rupture of atherosclerotic plaques remains a key public health goal.(1) Although 
our understanding of the pathogenesis underlying atherosclerosis has 
progressed over the last two decades, accurate prediction of clinical events 
remains elusive. There is therefore considerable interest in non-invasive 
imaging techniques that go beyond the detection of luminal stenoses and 
instead focus on measuring disease activity within the vasculature.(2,3)
Combined positron emission tomography (PET) and computed tomography 
(CT) is a non-invasive hybrid imaging technique that integrates targeted 
functional molecular imaging with high-detail anatomical definition. This 
technique has been used to quantify vascular inflammation and calcification 
activity with success in both carotid and coronary atherosclerosis.(4-7) 
Recently, intraplaque angiogenesis and neovascularization has emerged as a 
key factor in the development, progression, and instability of atherosclerotic 
plaques.(8) The integrin αvβ3 cell surface receptor is upregulated on endothelial 
cells in states of angiogenesis and is also observed on macrophages at sites 
of increased vascular inflammation, another key contributor to plaque 
instability. This receptor helps coordinate interaction between cellular 
components and the extra-cellular matrix, and contains a distinctive RGD-
amino acid sequence (the arginine-glycine-aspartate motif) in the cell-ligand 
interaction site. On this basis, several PET tracers targeting the RGD sequence 
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have been developed for monitoring angiogenesis in malignant tumours.(9,10) 
These tracers have also shown promise in monitoring atherosclerotic activity in 
pre-clinical models (8,11-14) and in a recent small study of patients with carotid 
atheroma.(7)
18F-Fluciclatide is a novel RGD-based PET radiotracer with high affinity for the 
αvβ3 integrin receptor.(10,15,16) We hypothesized that 18F-fluciclatide may act 
as an imaging marker of atherosclerotic disease activity in vivo, informing about 
both inflammation and angiogenesis. In this study, we sought to characterize 
the cellular and imaging characteristics of 18F-fluciclatide uptake in human 
atherosclerosis using a clinical cohort of patients with both stable and unstable 
clinical disease. 
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Methods
Study populations
In total we studied 50 patients. Four patients were recruited who had sustained 
a recent stroke and were undergoing carotid endarterectomy. In these patients, 
excised carotid plaques were examined using histology and 18F-fluciclatide 
autoradiography. For in vivo imaging, 46 patients were recruited from the Royal 
Infirmary of Edinburgh between July 2013 and December 2014. This cohort 
comprised 19 unstable patients with a recent acute ST-segment elevation 
myocardial infarction (MI) (14±7 days after MI) (NCT01813045),(17) and 27 
stable patients with either stable angina (n=6) or asymptomatic atherosclerotic 
disease (n=21; 12 had calcific aortic valve disease) (NCT01837160). Exclusion 
criteria were age <40 years, women of childbearing potential, severe renal 
failure (estimated glomerular filtration rate <30 mL/min) or hepatic failure 
(Childs-Pugh grade B or C), atrial fibrillation, known contrast allergy, inability to 
undergo scanning and inability to provide informed consent. All 46 subjects 
underwent 18F-fluciclatide PET imaging alongside clinical assessment that 
included evaluation of cardiovascular risk and high sensitivity C-reactive protein 
(hs-CRP) measurement (Biocheck inc.; Foster City, California).
Studies were approved by the local research ethics committee and conducted 
in accordance with the Declaration of Helsinki and with written informed 
consent of each participant. 
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Radiosynthesis of 18F-Fluciclatide
18F-Fluciclatide was manufactured at the Clinical Research Imaging Centre on 
an automated module (FASTlab synthesiser; GE Healthcare) by coupling an 
amino-oxy-functionalized peptide precursor (AH111695) with 4-18F-
fluorobenzaldehyde at pH 3.5 to form 18F-fluciclatide.(17) A full description of 
this synthesis has been published previously.(16)
Histological Validation
Carotid endarterectomy specimens (Data Supplement) were fresh frozen and 
sectioned in cryosection medium. Both atheromatous and non-atheromatous 
segments were fixed, stained with hematoxylin-eosin (HE) and examined by 
immunohistochemistry for smooth muscle actin, CD31, CD68, and αvβ3 integrin 
receptor expression before digital image capture (Axioscan.Z1, Zeiss, UK). 
Image analysis was performed on ImageJ32 software (NIH, Bethesda, 
Maryland). Staining was expressed as a percentage of the total plaque area 
and with an object size set threshold applied at 20 x 10 pixels, to limit counting 
to cell-sized objects. The density of cell staining in the endarterectomy tissue 
was expressed as cells per mm2.(18)
Autoradiography was performed to identify the precise localization of 18F-
fluciclatide binding in atherosclerotic tissue. Carotid sections were bathed in a 
solution of 18F-fluciclatide (1 kBq/mL) for 60 min and rinsed with phosphate 
buffer solution. To rule out non-specific radiotracer uptake, an un-labeled highly 
concentrated solution of fluciclatide was added to bind competitively with the 
αvβ3 integrin receptors. 18F-Fluciclatide binding was imaged using a FujiFilm 
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9
FLA-5100 Fluorescent Image Analyser (Raytek Scientific Limited, Sheffield, 
UK). 
Clinical 18F-Fluciclatide PET Imaging 
All patients in the imaging cohort underwent PET-CT imaging of the thorax with 
a hybrid scanner (Biograph mCT, Siemens Medical Systems, Erlangen, 
Germany) at the Clinical Research Imaging Centre, University of Edinburgh. 
Subjects were administered a target dose of 230 MBq 18F-fluciclatide. An 
attenuation correction CT scan (non-enhanced 120 kV and 50 mA, 3-mm 
slices) was performed prior to PET acquisition. To define tracer 
pharmacodynamics and the optimum timing of scanning, dynamic PET imaging 
of the thorax was performed in the initial 20 patients in 3-dimensional mode 
using a single bed position for 70 min. For the remainder of the study subjects, 
static imaging was performed at the optimal time point (found to be 40 min post-
injection) using a single 30-min bed position in list mode with 
electrocardiographic gating. Immediately after PET acquisition, thoracic CT 
angiography was performed. (Data Supplement)
PET Image Reconstruction and Analysis
Kinetic analysis was performed on the dynamic PET studies to investigate the 
pharmacodynamics of 18F-fluciclatide uptake within atheroma. The 
methodology is described in detail in the data supplement. In all patients, static 
electrocardiogram-gated PET images were reconstructed in diastole (40-70 
min post-injection, 50–75% of the R-R interval, Ultra-HD, 2 iterations, 21 
subsets, zoom x2, 200 pixels). Images were analyzed by experienced 
observers blinded to the demographic data (WJ, AV) using an OsiriX 
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10
workstation (OsiriX version 6.0 64-bit; OsiriX Imaging Software, Geneva, 
Switzerland). PET images were fused with the attenuation correction CT, and 
regions of interest (ROIs) drawn around the thoracic aorta on serial axial slices 
just beyond the discernible adventitial border. Aortic uptake was assessed in 
three regions: the ascending thoracic aorta (from the level of mid-right 
pulmonary artery (RPA) up to the last slice where the aorta maintained its 
circular cross-sectional appearance), the descending thoracic aorta (the region 
extending from the tip of the diaphragm up to the last circular slice) and the 
aortic arch (the regio  of the aorta connecting the ascending and descending 
aorta). Within these regions, mean and maximum tracer activities were 
measured using standard uptake values (SUV; the decay corrected tissue 
concentration of the tracer divided by the injected dose per body weight, 
kBq/mL) and corrected for mean radiotracer blood pool activity to provide a 
mean of the maximum tissue-to-background ratio (mean TBRmax).(5,19-20) The 
blood pool radiotracer activity was quantified in the superior vena cava (SVC), 
measured in the axial plane on 4-5 sequential 5-mm axial slices above the level 
of the junction of the left innominate vein. In a sub-study of 10 randomly 
selected subjects, images were assessed independently by two experienced 
observers and the inter-observer reproducibility of 18F-fluciclatide SUV and 
TBR measurements assessed. 
CT Image Reconstruction and Analysis
The aortic CT calcium score was calculated for the aorta as a whole and for its 
different regions using axial slices on the attenuation correction CT dataset 
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11
(OsiriX version 6.0 64-bit; OsiriX Imaging Software, Geneva, Switzerland) and 
expressed in arbitrary units (AU).(21) In those patients whose descending aorta 
was visualised within contrast CT datasets (n=33), further measures of aortic 
atherosclerotic plaque burden were made on dedicated plaque analysis 
software (Vital Images, Minnetonka, Minnesota, USA). Using the sagittal plane, 
the entire portion of the descending thoracic aorta within the field of contrast 
CT acquisition was delineated and the luminal blood pool removed using semi-
automated thresholding. The mean aortic wall thickness was recorded and 
corrected for the vessel diameter providing the indexed wall thickness. 
Additionally, the aortic wall volume was recorded and corrected for total vessel 
volume to provide an indexed plaque volume. 
 
Statistical analysis
Continuous data were tested for normality visually and with the D’Agostino and 
Pearson Omnibus test.  Continuous parametric variables were expressed as 
mean±standard deviation and compared using Pearson correlation. Non-
parametric data were presented as median [interquartile range] and compared 
using Spearman correlation or Wilcoxon signed-rank test as appropriate. Aortic 
calcium score and hs-CRP were log-transformed to base 10 to achieve 
normality prior to statistical analysis. Interobserver reproducibility was 
calculated by Bland Altman method and presented as mean bias ± 2 standard 
deviations, and intraclass correlation coefficients (ICC).(22) Student’s t-test or 
Mann-Whitney U test was used for analysis of categorical variables. Statistical 
analysis was performed with Graph Pad Prism version 6 (GraphPad Software 
Inc., California USA). A two-sided P<0.05 was taken as statistically significant.
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Results
Plaque Autoradiography and Histology 
Autoradiography of carotid plaque demonstrated focal 18F-fluciclatide binding 
in regions of advanced atherosclerosis that was effectively blocked by un-
labeled fluciclatide (Figure 1 A and B). On adjacent tissue sections processed 
for histology, these regions of ex vivo 18F-fluciclatide uptake co-localised with 
areas of intense cellular staining of αvβ3 integrin (45.2 [29.1-66.9] cells/mm2, % 
area 4.2 [3.2-5.7]), microvascular endothelial cells at sites of angiogenesis and 
positive remodeling (CD31+; 23.0 [6.5-63.0] cells/mm2, % area 2.5 [2.2-4.9]), 
and inflammatory macrophages deeper adjacent to the necrotic core (CD68+; 
32.0 [21.0-49.8] cells/mm2, % area 3.7 [2.4-5.6], Figure 1 C-H). By comparison 
regions of carotid endarterectomy specimen without visible atheroma did not 
demonstrate 18F-fluciclatide uptake, and had much lower levels of αvβ3 integrin 
receptor expression (4.5 [4.3-5.2] cells/mm2, % area 0.6 [0.5-2.0], both p=0.05 
compared to areas with increased 18F-fluciclatide expression), as well as 
staining for both angiogenic endothelial cells (CD31+; 2.1 [1.8-2.4] cells/mm2, 
% area 0.9 [0.6-1.2], both p=0.05) and inflammatory macrophages (CD68+; 4.3 
[2.8-4.4] cells/mm2, % area 0.6 [0.5-1.2], both p=0.03) .
In Vivo Imaging Cohort 
A total of 46 subjects underwent PET imaging with CT angiography (age 66±10 
years, 74% male; Table 1) following injection of 226±13 mBq 18F-fluciclatide. 
Of the 46 subjects recruited, 19 had suffered a recent MI (unstable cohort), and 
27 had imaging evidence of aortic atherosclerosis on CT but no recent 
cardiovascular events (stable cohort: 6 with stable angina and 21 with sub-
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clinical disease who were asymptomatic with no prior cardiovascular events). 
Interestingly, those in the stable cohort had greater aortic calcification than 
patients in the unstable group (AU [IQR]; 326 [11-1114] vs 19 [0-483], p<0.01), 
reflecting their greater age (years; 70±8 vs 61±12, p<0.01). The groups were 
well matched for gender (p=0.97) and body-mass index (p=0.25), and were 
both characterized by high prevalence of atherosclerotic risk factors, with more 
smokers in the unstable group (p=0.02) and more patients with hypertension in 
the stable group (p=0.001). No adverse events were reported following 
administration of 18F-fluciclatide and the average total radiation dose per 
participant was 15 mSv.
Dynamic Analysis of Aortic 18F-Fluciclatide Uptake
On kinetic analysis (n=20), activity within aortic atheroma increased gradually, 
reaching a plateau at 40–70 min. Injected 18F-fluciclatide activity has a 
biexponential blood pool clearance with a half-life of about 10 min consisting of 
a fast redistribution component with a slower clearance component, causing 
relatively high residual blood pool activity during PET acquisition (40-70 min 
post-injection, SVC SUVmean 2.74±0.49; Figure 2). Consequently, whilst 18F-
fluciclatide uptake in aortic atheroma was measurable above background, 
tissue-to-background ratios were relatively low (TBRmax ra ge 1.08-1.68; 
Tables 2 and 3, Figures 2 and 3). In the 3-D Patlak slope (Ki) parametric 
images, 6 datasets (30%) were uninterpretable due to patient movement. In the 
remaining studies, increased aortic 18F-fluciclatide uptake was observed in half 
of subjects. Patlak modelling demonstrated a discernible linear phase 
suggesting irreversible ligand-receptor binding over the selected acquisition 
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time and a greater Ki slope in these subjects compared to patients with no aortic 
uptake (Figure 2).  Subjects with uptake present on Patlak analysis (n=7) also 
appeared to have higher 18F-fluciclatide uptake on standard analysis (TBRmax 
1.32±0.05 vs 1.19±0.03, p=0.08) and greater aortic calcification (aortic calcium 
score 704 [28-1788] vs 0 [0-119] AU, p=0.06) than those without visible uptake, 
although this did not reach statistical significance. 
Aortic 18F-Fluciclatide Uptake Reproducibility Studies 
Using static PET images, quantification of 18F-fluciclatide blood-pool activity 
demonstrated excellent interobserver reproducibility, with no fixed or 
proportional bias (SUVmean mean difference; -0.11 [-0.36 – 0.15]) and a good 
intraclass correlation co-efficient (0.95, Table S1). Quantification of aortic 18F-
fluciclatide uptake using the established mean TBRmax approach (5,20) also 
displayed no fixed or proportional bias (mean difference; 0.08 [-0.01–0.16]) with 
good intra-class correlation (0.92) (Table S1).
Aortic 18F-Fluciclatide Uptake and Atheroma Burden
Our study cohort comprised patients with a wide spectrum of aortic 
atherosclerotic burden (aortic calcium score range 0-6857 AU). On static PET 
images, aortic 18F-fluciclatide uptake demonstrated a moderate relationship 
with disease burden in the aorta using both CT calcium scoring (r=0.37 [0.08-
0.60], p=0.01) and the indexed plaque volume (r=0.56 [0.26-0.75]; p<0.001) 
(Table 3, Figures 3 and 4). A good correlation was also observed with the 
relative vessel wall thickness (expressed as a percentage of vessel diameter, 
r=0.57 [0.28-0.76]; p<0.001). There was no correlation between aortic 18F-
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fluciclatide uptake and the inflammatory marker C-reactive protein (log10 hs-
CRP r=0.18, p=0.28). 
Aortic 18F-Fluciclatide Uptake in Stable and Unstable Patients
To establish whether 18F-fluciclatide uptake may be a marker of unstable 
atherosclerotic activity, we compared aortic uptake in patients who had 
sustained a recent MI to those in our stable cohort. Given the association 
demonstrated between 18F-fluciclatide activity and plaque burden, we matched 
patients in the two groups according to CT calcium score (Table S2). We 
demonstrated increased 18F-fluciclatide aortic uptake in patients with recent MI 
compared to those in the stable cohort (TBRmax; 1.33±0.15vs 1.21±0.1, 
p=0.008) despite equivalent aortic calcium scores (Table 2, Figure 4). 
Moreover, in patients with recent MI, a stronger correlation was observed 
between aortic plaque burden and 18F-fluciclatide uptake than in the patient 
population as a whole (aortic wall thickness r=0.68, p=0.02). When aortic SUV 
measurement were assessed, these were consistently increased in the 
unstable groups compared to the stable groups across all regions of the aorta, 
even before attempts were made to match these groups by calcium score 
(p<0.05 for all aortic regions, Table 2 and S3).
Aortic 18F-Fluciclatide and Cardiovascular Risk Factors
Amongst patients in the stable cohort, aortic 18F-fluciclatide uptake correlated 
with a number of risk factors (Table 3). 18F-Fluciclatide activity was higher in 
patients with hypercholesterolemia compared to those without (1.37±0.04 vs 
1.24±0.06, p=0.007). Apparent observed trends were also seen in patients with 
diabetes (1.41±0.08 vs 1.28±0.02, p=0.06) and those with a diagnosis of 
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coronary heart disease (1.37±0.04 vs 1.28±0.03, p=0.08), although these did 
not meet statistical significance. Again, a strong correlation was observed 
between 18F-fluciclatide uptake and the CT calcium score (r=0.62, p<0.001) in 
this subgroup.
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Discussion
We present the largest multimodality imaging study to date evaluating the 
application of an RGD-based αvβ3 integrin receptor radiotracer in the 
assessment of human atheroma. We have demonstrated that ex vivo 18F-
fluciclatide binding co-localises to sites of αvβ3 integrin receptor expression in 
excised carotid plaques, and this was associated with regions of both 
angiogenesis and inflammation. We have further demonstrated in vivo that 18F-
fluciclatide uptake increased with progressive atherosclerotic plaque burden 
and is higher in patients with unstable versus stable atherosclerotic disease. 
These data would suggest that 18F-fluciclatide holds promise as a non-invasive 
marker of disease activity in atherosclerosis, informing us about two key 
characteristics of high-risk atheroma: inflammation and angiogenesis. RGD-
based tracers may therefore aid our pathophysiological understanding of this 
important condition and help identify patients at increased risk of adverse 
cardiovascular events. 
Plaque inflammation and angiogenesis are two key pathological processes 
associated with atheroma progression, plaque rupture and clinical events. 
Macrophages drive expansion of the necrotic core and secrete matrix 
metalloproteinases that weaken the fibrous cap, predisposing it to rupture. 
Angiogenesis is believed to occur in response to hypoxic conditions within the 
necrotic core and is associated with high-risk plaque characteristics.(3) In 
addition, these new vessels are prone to leakage and rupture resulting in 
plaque hemorrhage that itself results in an pro-inflammatory response, plaque 
destabilization and clinical events. A non-invasive imaging technique that can 
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inform about the activity of these two adverse pathological processes might 
therefore be useful in identifying patients with active high-risk atheroma. 
Indeed, it is hoped that non-invasive markers of systemic atherosclerotic 
disease activity may identify the vulnerable patient and provide incremental risk 
prediction to an assessment of radiographic coronary or carotid disease burden 
alone.(2,23) We have here demonstrated that 18F-fluciclatide PET-CT is an 
emerging and promising approach to achieve these aims.
Our autoradiographic data showed focal 18F-fluciclatide binding within carotid 
atheroma that localised histologically to αvβ3 integrin expression with no 
evidence of non-specific binding. Regions of 18F-fluciclatide uptake on 
autoradiography also corresponded to sites of immunohistochemical cellular 
staining for vascular endothelial cells and macrophages. This is in keeping with 
previous RGD-radiotracer studies and supports its role as a selective marker 
for angiogenic and inflammatory components of atherosclerotic activity.(7, 
24,25) Due to the close relationship between intraplaque inflammation and 
angiogenesis however, we are unable to ascertain whether 18F-fluciclatide was 
binding preferentially to one or the other of these processes. 
Dynamic in vivo imaging studies in 20 subjects confirmed irreversible 18F-
fluciclatide binding to regions of aortic atherosclerosis over the selected 
acquisition time, and demonstrated that the optimum time for 18F-fluciclatide 
imaging in the aorta is between 40 and 70 min. This timeframe was used for 
subsequent static PET imaging across the cohort as a whole. Static in vivo 
imaging demonstrated reproducible quantification of 18F-fluciclatide in aortic 
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atheroma of all 46 patients, and this was correlated with the severity of aortic 
atherosclerotic burden, itself a manifestation of systemic atherosclerosis and a 
strong predictor of cardiovascular events.(26,27) Indeed associations were 
observed with the aortic calcium score, aortic wall thickness and overall plaque 
volume. In patients with clinically stable disease, aortic uptake of 18F-
fluciclatide was increased in subjects with hypercholesterolemia with trends 
towards higher uptake in patients with diabetes mellitus and those with 
ischemic heart disease that did not meet statistical significance.  Perhaps most 
importantly, 18F-fluciclatide uptake in aortic atheroma was increased in 
patients with unstable (recent MI) versus stable clinical disease. Interestingly, 
using 18F-fluorodeoxyglucose, we have previously demonstrated a similar 
pattern of increased metabolic activity in aortic atheroma amongst patients with 
recent MI.(28) These data therefore lend support to the hypothesis that acute 
MI causes inflammation and instability in systemic atherosclerosis, as has been 
suggested in preclinical murine models.(29) It also provides further validity to 
the concept that 18F-fluciclatide uptake can identify higher risk plaques. 
However, whether this increased disease activity truly represents a response 
to the infarct or rather the underlying trigger remains to be determined.
We acknowledge that there are some limitations of our study that include 
potential partial volume artefacts, a limited histological assessment and the use 
of surrogate measures for aortic histology. 18F-Fluciclatide imaging prior to 
carotid endarterectomy would allow for a more direct comparison between in-
vivo imaging and histological assessment and consolidate our findings in line 
with previous publications.(7) Furthermore, our exploratory assessment of 
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aortic plaque volume may not take into account non-atheromatous intimal 
thickening in response to chronic hypertension. The dynamic imaging approach 
proved sensitive to patient movement during the prolonged acquisition period, 
limiting its utility in quantitative analysis, but this may ultimately be readdressed 
by novel motion tracking systems that allow for correction of cardiac and 
respiratory motion, enabling even greater definition of regional αvβ3 integrin 
expression.(30) Nonetheless, we believe that the totality of our comprehensive 
evidence using multiple approaches and imaging modalities provides a robust 
and cogent argument to support our findings.
In conclusion, this is the largest study to date assessing αvβ3 integrin expression 
in human atherosclerotic disease. We have demonstrated that 18F-fluciclatide 
uptake localises to regions of inflammation and angiogenesis, correlates with 
the plaque burden and is increased in patients with clinically unstable disease. 
Although further study is required, our data indicate that 18F-fluciclatide shows 
promise as a non-invasive marker of disease activity and instability in 
atherosclerosis.
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Table 1. Patient Characteristics
All
(n=46)
Stable 
Atherosclerosis
(n=27)
Unstable 
Atherosclerosis
(n=19)
P value*
Age (years) 66±10 70±8 61±12 0.006
Male Sex 34 (74) 20 (74) 14 (74) 0.97
BMI (kg/m2) 28±4 28±4 29±5 0.25
Systolic BP (mmHg) 140±22 149±19 127±19 <0.001
18F-Fluciclatide dose 
(MBq) 226±13 225±13 228±14 0.62
Cardiovascular History
Angiographically 
documented CAD 26 (57) 7 (26) 19 (100) <0.001
Prev MI 24 (52) 5 (19) 19 (100) <0.001
Prev PCI 20 (43) 2 (7) 18 (95) <0.001
Prev CVD 4 (11) 4 (14) 0 (0) 0.08
Risk Factors
Current smoker 9 (20) 1 (4) 8 (42) 0.001
Diabetes Mellitus 6 (13) 4 (14) 2 (10) 0.58
Prior hypertension 23 (50) 18 (67) 6 (32) 0.02
Prior Hypercholester-
olemia 25 (54) 12 (44) 12 (63) 0.21
hs-CRP (mg/l) 3.5 [1.4-7.8] 2.7 [1.4-5.8] 5.6 [2.0-11.7] <0.001
Log10 hs-CRP (mg/l) 0.51±0.51 0.41±0.44 0.65±0.56 <0.001
Medications
Aspirin 28 (61) 10 (37) 19 (100) <0.001
Clopidogrel 19 (41) 4 (14) 19 (100) <0.001
Statin 31 (67) 13 (48) 19 (100) <0.001
β-Blocker 27 (59) 8 (30) 19 (100) <0.001
ACEi/ARB 31 (67) 10 (37) 18 (95) <0.001
Calcium Channel 
Blocker 7 (15) 6 (22) 1 (5) 0.11
Categorical data are displayed as n (%). Normally distributed data displayed as 
mean±SD. Non-normally distributed data displayed as median [interquartile range]. 
IHD - ischemic heart disease; AS - aortic stenosis; CAD - coronary artery disease; MI 
- myocardial infarction; CVD – cerebrovascular disease; PCI - percutaneous 
coronary intervention; hs-CRP - high sensitivity c-reactive protein; ACEi - ACE-
inhibitor; ARB - Angiotensin Receptor Blocker. 
* P-values are quoted for comparisons between matched stable and unstable groups.  
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Table 2. Imaging Results
All
(n=46)
Stable 
Atherosclerosis
(n=27)
Matched Stable 
Atherosclerosis 
(n=19) Ψ
Unstable 
Atherosclerosis
(n=19)
P 
value*
18F-Fluciclatide PET uptake
SVC
(SUVmean)
2.74±0.49 2.62±0.46 2.54±0.40 2.9±0.48 0.02
Whole aorta 
(mean SUVmax)
3.59±0.62 3.40±0.62 3.19±0.65 3.84±0.55 0.001
Whole aorta 
(mean TBRmax)
1.32±0.14 1.30±0.12 1.26±0.09 1.33±0.18 0.14
Ascending aorta 
(mean TBRmax)
1.32±0.16 1.31±0.17 1.25±0.10 1.34±0.17 0.05
Aortic Arch
(mean TBRmax)
1.30±0.14 1.26±0.14 1.21±0.1 1.33±0.15 0.008
Descending aorta 
(mean TBRmax)
1.32±0.17 1.32±0.13 1.29±0.11 1.33±0.21 0.56
CT Calcium Score 
Whole aorta (AU) 95 [0-852] 326 (11-1114) 36 (0-469) 19 [0-483) 0.85
Ascending aorta (AU) 0 [0-11] 0 (0-46) 0 (0-0) 0 [0-0} 0.15
Aortic arch (AU) 29 [0-352] 102 (0-586) 13 (0-469) 0 [0-263]
0.76
Descending aorta (AU) 7.5 [0-78] 0 (0-123) 0 (0-123) 8 [0-71] 0.43
CTA Plaque analysis (descending aorta)
Mean wall thickness
(% vessel diameter)
10.3±4.9 8.4±2.8 8.4±3.1 14.0±6.3 0.003
Plaque burden
(% total volume)
9.1±3.9 7.7±2.3 7.7±2.5 12.0±4.7 0.004
Ψ Stable group subjects paired to equivalent calcium score in unstable group.
 * P-values are quoted for comparisons between matched stable and unstable 
groups.  
SUV - standard uptake value; SVC – superior vena cava; TBR - tissue-to-
background ratio
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Table 3. PET uptake and baseline characteristics
Total Aortic 18F-Fluciclatide Uptake 
All patients Stable Cohort Unstable Cohort
Continuous variables
CT calcium score 
(Log10AU) 
r=0.37 (0.08-0.60)
p=0.01
r=0.62 (0.43-0.81)
p<0.001
r=0.20 (-0.28-0.60)
p=0.41
Mean wall thickness 
(% vessel diameter) Ψ
r=0.57 (0.28-0.76)
p<0.001
r=0.18 (-0.26-0.56)
p=0.43
r=0.69 (0.15-0.91)
p=0.02
Plaque volume 
(% total volume) Ψ
r=0.56 (0.26-0.75)
p<0.001
r=0.16 (-0.28-0.55)
p=0.47
r=0.68 (0.13-0.90)
p=0.02
Log10 hs-CRP (mg/l)
r=0.18 (-0.14-0.46)
p=0.28
r=0.32 (-0.07-0.62)
p=0.10
r=-0.24 (-0.63-0.24)
p=0.06
Categorical variables
Hypertension 
(mean TBRmax)
1.31±0.05 vs
1.32±0.04
p=0.66
1.31±0.05 vs
1.32±0.04
p=0.66
Established Ischemic 
Heart Disease
(mean TBRmax)
1.34±0.06 vs
1.28±0.06
0.15
1.37±0.04 vs
1.28±0.03
0.08
Hypercholesterolemia
(mean TBRmax)
1.34±0.06 vs
1.28±0.06
p=0.16
1.37±0.04 vs
1.24±0.06
p=0.007
Diabetes mellitus
(mean TBRmax)
1.40±0.10 vs
1.30±0.05
p=0.15
1.41±0.08 vs
1.28±0.02
p=0.06
Current Smokers
(mean TBRmax)
1.36±0.10 vs
1.30±0.04
p=0.30
N too small
Ψ18F-Fluciclatide uptake assessed in the descending aorta only, to correspond with 
CT analysis. 
CT – computed tomography; hs-CRP - high sensitivity C-reactive protein
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Figure 1. 18F-Fluciclatide Uptake in Carotid Atheroma
(A) Autoradiography image of segments of ruptured carotid plaque (left) and proximal 
healthy segments (right). Greater 18F-fluciclatide binding is visible within plaque 
rupture segments. Binding within the tissue segments (demarcated, black) was 
successfully blocked by the addition of a more concentrated un-labelled solution of 
fluciclatide (B).  Areas showing the highest fluciclatide binding (demarcated, blue) 
exhibited a high degree of αvβ3 integrin expression (C and D, arrow) that also 
featured cellular staining for vascular endothelial cells (CD31, E and F, arrow) and 
inflammatory cells (CD68, G and H, arrow). Scale bar 1 mm in C, E, G  and 75 μm 
in D, F, H. 
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Figure 2. Kinetic Analysis of Aortic 18F-Fluciclatide Uptake
Sagittal views of the thorax following kinetic analysis in two participants with 
(patient 1: A-E) and without (patient 2; F-H) aortic arch 18F-fluciclatide uptake. 
Computed tomography (CT) images confirm presence (A) or absence (F) of 
aortic arch calcification as a marker of established atheroma. Patlak slope (Ki) 
parametric images (B and G) identify focal uptake within the aortic arch in the 
region of atheroma (red arrow) localising to the vessel wall on the fused Patlak 
and CT images (C and H). Patlak modelling (D) confirms irreversible integrin 
binding within the region of aortic arch calcification (red arrow). Time activity 
curves (TAC) within the same region (E) show a persistently high blood pool 
fraction, but uptake within atheroma that exceeds the blood pool fraction 
beyond 40 min (dashed line).
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Figure 3. 18F-Fluciclatide Aortic Uptake
Patient 3: Modified coronal view of the aortic arch showing radiotracer uptake 
at the inner curvature of the aortic arch related to a region of aortic calcification. 
This activity is demonstrated on axial sections of the aorta (i and ii). Red lines 
indicate the adventitial borders of the aortic arch used for quantification of PET 
uptake. Patient 4: Sagittal view of the thorax displaying focal 18F-fluciclatide 
uptake within a region of vascular calcification in the aortic arch. 
Page 31 of 44
https://mc.manuscriptcentral.com/heart
Heart
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
31
Figure 4. 18F-Fluciclatide Uptake, Atheroma Burden and Clinical 
Stability
Graphs displaying the relationship between aortic 18F-fluciclatide uptake and 
aortic plaque burden, assessed using both the plaque volume (A) and calcium 
score (B). Moreover 18F-Fluciclatide uptake was greater in patients with 
unstable (recent myocardial infarction) versus stable (no recent cardiovascular 
events) atherosclerotic disease (C).
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Figure 1. 18F-Fluciclatide Uptake in Carotid Atheroma 
(A) Autoradiography image of segments of ruptured carotid plaque (left) and proximal healthy segments 
(right). Greater 18F-fluciclatide binding is visible within plaque rupture segments. Binding within the tissue 
segments (demarcated, black) was successfully blocked by the addition of a more concentrated un-labelled 
solution of fluciclatide (B).  Areas showing the highest fluciclatide binding (demarcated, blue) exhibited a 
high degree of αvβ3 integrin expression (C and D, arrow) that also featured cellular staining for vascular 
endothelial cells (CD31, E and F, arrow) and inflammatory cells (CD68, G and H, arrow). Scale bar 1 mm in 
C, E, G  and 75 μm in D, F, H. 
190x253mm (225 x 225 DPI) 
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STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies 
Item 
No Recommendation
Page
No
(a) Indicate the study’s design with a commonly used term in the title or 
the abstract
2Title and abstract 1
(b) Provide in the abstract an informative and balanced summary of what 
was done and what was found
2
Introduction
Background/rationale 2 Explain the scientific background and rationale for the investigation being 
reported
5
Objectives 3 State specific objectives, including any prespecified hypotheses 6
Methods
Study design 4 Present key elements of study design early in the paper 7
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection
7-9
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection 
of participants
7
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, 
and effect modifiers. Give diagnostic criteria, if applicable
9-10
Data sources/ 
measurement
8*  For each variable of interest, give sources of data and details of methods 
of assessment (measurement). Describe comparability of assessment 
methods if there is more than one group
9-10
Bias 9 Describe any efforts to address potential sources of bias 11
Study size 10 Explain how the study size was arrived at
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why
7-11
(a) Describe all statistical methods, including those used to control for 
confounding
11
(b) Describe any methods used to examine subgroups and interactions 11
(c) Explain how missing data were addressed
(d) If applicable, describe analytical methods taking account of sampling 
strategy
11
Statistical methods 12
(e) Describe any sensitivity analyses 11
Results
(a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included 
in the study, completing follow-up, and analysed
12
(b) Give reasons for non-participation at each stage
Participants 13*
(c) Consider use of a flow diagram
(a) Give characteristics of study participants (eg demographic, clinical, 
social) and information on exposures and potential confounders
25Descriptive data 14*
(b) Indicate number of participants with missing data for each variable of 
interest
Outcome data 15* Report numbers of outcome events or summary measures
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make clear 
which confounders were adjusted for and why they were included
12-
16
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(b) Report category boundaries when continuous variables were 
categorized
12-
16
(c) If relevant, consider translating estimates of relative risk into absolute 
risk for a meaningful time period
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, 
and sensitivity analyses
Discussion
Key results 18 Summarise key results with reference to study objectives 17-
20
Limitations 19 Discuss limitations of the study, taking into account sources of potential 
bias or imprecision. Discuss both direction and magnitude of any potential 
bias
17-
20
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence
17-
20
Generalisability 21 Discuss the generalisability (external validity) of the study results 17-
20
Other information
Funding 22 Give the source of funding and the role of the funders for the present study 
and, if applicable, for the original study on which the present article is 
based
21
*Give information separately for exposed and unexposed groups.
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at www.strobe-statement.org.
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Supplementary Text and Data
Computed Tomography Acquisition
Immediately after PET acquisition, thoracic CT angiography was performed: 330 ms 
rotation time, 100 (body mass index <25 kg/m2) or 120 (body mass index >25 kg/m2) kV 
tube voltage, 160-245 mAs tube current, 3.8 mm/rotation table feed, prospective (heart 
rate regular and <60 /min), or retrospective (heart rate >60 /min) electrocardiogram-gated. 
Depending on body mass index, a bolus of 80-100 mL contrast (400 mgI/mL; Iomeron, 
Bracco, Milan, Italy) was injected intravenously at 5 mL/s, after determining the 
appropriate trigger delay with a test bolus of 20 mL contrast material. 
PET Imaging 
Kinetic Analysis
PET data were reconstructed (Ultra-HD, 2 iterations, 21 subsets, 256 pixels, 1.6-mm pixel size) 
in a dynamic profile using the following time frames; 60s x 5, 120s x 5, 180s x 5, 300s x 8. 
Regions of interest (ROI’s) were drawn both in the blood pool and sites of aortic atheroma 
visible on CT and used to derive time activity curves after decay correction. These were used to 
define a timeframe for static imaging based upon the point at which optimum contrast 
between blood pool and tissue activity was observed. To define 18F-fluciclatide uptake in aortic 
atheroma, a kinetic modeling input function calculation was based on the PET image-derived 
activity curve from the aortic blood pool.(8) (PMod version 4.3.1, Pmod technologies limited, 
Switzerland). This input function was applied to a tissue activity curve generated from ROI’s 
placed in the myocardial interventricular septum, to estimate the tissue influx rate Ki (the slope 
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of the linear regression) and the volume of distribution (the intercept with the y axis) using a 2-
tissue irreversible Patlak model, with t* set to 20 min, as described previously (9,11). Thoracic 
18F-fluciclatide dynamic activity was then normalized for the blood-pool input function on a 
voxel-by-voxel basis, and after 3D Gaussian filtering (5-mm FWHM), a parametric 3-dimensional 
image of 18F-fluciclatide uptake was generated accordingly. Using this image, regions of 18F-
fluciclatide binding in the vasculature were identified and manually delineated for subsequent 
Ki analysis. 
Histological Processing and Analysis
After obtaining informed consent, four human carotid intimal samples were obtained from 
patients undergoing carotid endarterectomy for symptomatic carotid artery atherosclerotic 
disease. Segments of dissected carotid atheroma were frozen in mounting medium. The tissue 
samples were then cut in sequential, longitudinal 4 μm and 20 μm slices sections at -20°C and 
thaw-mounted onto microscope slides. Effort was made to align segments of ruptured plaque 
alongside non-atheromatous segments within the same slide. The slides were then dried for 15 
min and spray-fixed with neutral buffered formalin. After rinsing in distilled water the 4 μm 
sections were stained with hematoxylin-eosin (HE) and van-Gieson (VG) for conventional 
histopathological examination. In order to optimize immunohistochemistry, an antigen-
unmasking step was performed by microwave treatment for 30 s. Endogenous peroxidase was 
blocked by incubation with hydrogen peroxide for 5 min. Sections were subsequently incubated 
with the primary antibodies; smooth muscle actin, CD31, CD68 (clone PG-M1), and integrin αVβ3 
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antibody, clone LM609 (Millipore) for 30 min at room temperature. After washing, the sections 
were incubated with Envision Flex (DAKO, K5007) for 30 min at room temperature, followed by 
incubation with diaminobenzamine (Sigma) for 10 min. The slides were finally counterstained 
with hematoxylin and digitally imaged (Axioscan.Z1, Zeiss, UK).
Clinical PET systems have limited resolution. To gain more detailed information about the 
precise localization of 18F-fluciclatide binding in atherosclerotic tissue, we undertook 
autoradiography. The 20 μm frozen sections adjacent to those used for immunohistochemical 
analysis were warmed to room-temperature and bathed in a solution of 18F-fluciclatide at a 
concentration close to in vivo imaging concentrations (1 kBq/mL) for 60 minutes and then 
rinsed with phosphate buffer solution. An unlabeled highly concentrated solution of fluciclatide 
was added to selected slides in order to competitively bind to αvβ3 to assess for non-specific 
tracer uptake. A freshly blanked phosphor screen was then placed over the slides and an 
overnight exposure undertaken. The screen was read using a FujiFilm FLA-5100 Fluorescent 
Image Analyser (Raytek Scientific Limited, Sheffield, UK). Sections were then manually 
registered and examined for co-localization with histological markers of atherosclerotic disease 
activity. 
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Table S1 – Reproducibility Analysis
18F-Fluciclatide
Activity
Mean absolute differencea
Intra-class 
coefficientb
Superior Vena Cava 
Mean SUV (SUV [kBq/cc]) -0.11 (-0.36 – 0.15) 0.947
Aorta
Mean SUV (SUV [kBq/cc]) -0.005 (-0.14 – 0.13) 0.986
Mean SUVMDS (SUV [kBq/cc]) 0.01 (-0.17 – 0.15) 0.980
Max SUV (SUV [kBq/cc]) 0.07 (-0.13 – 0.27) 0.971
Max SUVMDS (SUV [kBq/cc]) 0.06 (-0.22 – 0.34) 0.957
Mean TBR 0.04 (-0.02 – 0.10) 0.954
Mean TBRMDS 0.04 (-0.04 – 0.10) 0.940
Max TBR 0.08 (-0.01 – 0.16) 0.912
Max TBRMDS 0.07 (-0.03 – 0.17) 0.919
SUV Target-background 0.19 (-0.05 – 0.43) 0.612
a Mean difference between TBRmax measurements (95% limits of agreement), and b ICC values 
for 18F-Fluciclatide throughout the thoracic aorta and SVC.
Abbreviations: ICC: intraclass correlation coefficient; MDS: most diseased segment; TBR: tissue to background 
ratio; SVC: Superior Vena Cava
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Table S2 – Baseline demographic data
Categorical data are displayed as n (%). Normally distributed data displayed as mean±SD. Non-
normally distributed data displayed as median [interquartile range]. 
IHD - ischemic heart disease; AS - aortic stenosis; CAD - coronary artery disease; MI - 
myocardial infarction; CVD – cerebrovascular disease; PCI - percutaneous coronary 
intervention; hs-CRP - high sensitivity c-reactive protein; ACEi - ACE-inhibitor; ARB - 
Angiotensin Receptor Blocker. 
* P-values are quoted for comparisons between matched stable and unstable groups.  
All
(n=46)
Stable 
Atherosclerosis
(n=27)
Stable 
atherosclerosis; 
matched group 
(n=19)
Unstable 
Atherosclerosis
(n=19)
P value
Age (years) 66±10 70±8 68±7 61±12 0.04
Male Sex 34 (74) 20 (74) 15 (79) 14 (74) 0.71
BMI (kg/m2) 28±4 28±4 26±4 29±5 0.59
Systolic BP (mmHg) 140±22 149±19 151±18 127±19 <0.001
18F-Fluciclatide dose 
(MBq) 226±13 225±13 225±13 228±14 0.55
Cardiovascular History
Angiographically 
documented CAD 26 (57) 7 (26) 1 (5) 19 (100) <0.001
Prev MI 24 (52) 5 (19) 0 (0) 19 (100) <0.001
Prev PCI 20 (43) 2 (7) 0 (0) 18 (95) <0.001
Prev CVD 4 (11) 4 (14) 3 (16) 0 (0) 0.08
Risk Factors
Current smoker 9 (20) 1 (4) 0 (0) 8 (42) 0.001
Diabetes Mellitus 6 (13) 4 (14) 2 (11) 2 (11) 0.99
Prior hypertension 23 (50) 18 (67) 11 (58) 6 (32) 0.11
Prior Hypercholester-
olemia 25 (54) 12 (44) 6 (32) 12 (63) 0.03
hs-CRP (mg/l) 3.5 [1.4-7.8] 2.7 [1.4-5.8] 3.0±2.4 5.6 [2.0-11.7] <0.001
Log10 hs-CRP (mg/l) 0.51±0.51 0.41±0.44 0.48±0.38 0.65±0.56 <0.001
Medications
Aspirin 28 (61) 10 (37) 5 (26) 19 (100) <0.001
Clopidogrel 19 (41) 4 (14) 3 (16) 19 (100) <0.001
Statin 31 (67) 13 (48) 5 (26) 19 (100) <0.001
β-Blocker 27 (59) 8 (30) 2 (11) 19 (100) <0.001
ACEi/ARB 31 (67) 10 (37) 4 (21) 18 (95) <0.001
Calcium Channel 
Blocker 7 (15) 6 (22) 4 (21) 1 (5) 0.11
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Table S3 – Imaging Results
All
(n=46)
Stable 
Atherosclerosis
(n=27)
Matched Stable 
Atherosclerosis 
(n=19) Ψ
Unstable 
Atherosclerosis
(n=19)
P 
value*
18F-Fluciclatide PET uptake
SVC
(SUVmean)
2.74±0.49 2.62±0.46 2.54±0.40 2.9±0.48 0.02
Whole aorta 
(mean SUVmax)
3.59±0.62 3.40±0.62 3.19±0.65 3.84±0.55 0.001
Ascending aorta
(mean SUVmax)
3.60±0.66 3.42±0.70 3.16±0.56 3.87±0.51 <0.001
Aortic Arch
(mean SUVmax)
3.51±0.62 3.29±0.61 3.05±0.52 3.84±0.48 <0.001
Descending aorta 
(mean SUVmax)
3.61±0.68 3.46±0.65 3.28±0.65 3.83±0.66 0.01
Whole aorta 
(mean TBRmax)
1.32±0.14 1.30±0.12 1.26±0.09 1.33±0.18 0.14
Ascending aorta 
(mean TBRmax)
1.32±0.16 1.31±0.17 1.25±0.10 1.34±0.17 0.05
Aortic Arch
(mean TBRmax)
1.30±0.14 1.26±0.14 1.21±0.1 1.33±0.15 0.008
Descending aorta 
(mean TBRmax)
1.32±0.17 1.32±0.13 1.29±0.11 1.33±0.21 0.56
CT Calcium Score 
Whole aorta (AU) 95 [0-852] 326 (11-1114) 36 (0-469) 19 [0-483) 0.85
Ascending aorta (AU) 0 [0-11] 0 (0-46) 0 (0-0) 0 [0-0} 0.15
Aortic arch (AU) 29 [0-352] 102 (0-586) 13 (0-469) 0 [0-263]
0.76
Descending aorta (AU) 7.5 [0-78] 0 (0-123) 0 (0-123) 8 [0-71] 0.43
CTA Plaque analysis (descending aorta)
Mean wall thickness
(% vessel diameter)
10.3±4.9 8.4±2.8 8.4±3.1 14.0±6.3 0.003
Plaque burden
(% total volume)
9.1±3.9 7.7±2.3 7.7±2.5 12.0±4.7 0.004
Ψ Stable group subjects paired to equivalent calcium score in unstable group.
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7
 * P-values are quoted for comparisons between matched stable and unstable groups.  
SUV - standard uptake value; SVC – superior vena cava; TBR - tissue-to-background ratio
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